The Cell DIVE scalable multiplexing platform allows researchers to select from over 350 rigorously validated antibodies to design their studies and a workflow to image 60+ biomarkers in a single tissue section. Cancer researchers can map normal and diseased tissue by cell type, biomarker profile, and specific features.
Leica Microsystems
Wetzlar, Germany